Cash, cash equivalents and marketable securities totaled $168.0 million as of December 31, 2024. This balance excludes net proceeds from our IPO of $199.6 million after deducting underwriting discounts and commissions and other offering costs. With the net IPO proceeds, Sionna expects its current cash position to fund operations into 2028.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Okta upgraded, Quest Diagnostics downgraded: Wall Street’s top analyst calls
- Sionna Therapeutics initiated with a Buy at TD Cowen
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
- Innovative Approach to Cystic Fibrosis Treatment: Sionna Therapeutics’ Pioneering Pipeline Earns Buy Rating
- Sionna Therapeutics initiated with a Buy at Stifel